Avoiding Narcotics in Post-Surgery Cancer Pain Management

​ Opioid addiction, which is currently so widespread that it amounts to a national crisis, often starts with the legitimate use of prescription pain medication after surgery or as a result of another medical condition. For this reason, it is essential to develop non-narcotic strategies to handle pain. A team of researchers in the Perelman School of Medicine at the University of Pennsylvania did just that, designing a program that successfully managed post-surgery pain for patients with urol...
Continue reading

Avelumab/Axitinib Approved: Advanced Renal Cell Carcinoma

​ The FDA has approved avelumab (Bavencio®, EMD Serono, Inc.) in combination with axitinib (Inlyta®, Pfizer Inc.) as first-line treatment for advanced renal cell carcinoma (RCC). Avelumab is an anti–programmed death ligand 1 (anti–PD-L1) antibody, a type of immune checkpoint inhibitor. Axitinib, a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), improves tumor infiltration by immune cells. It has antiangiogenic activity, meaning that it prevents tumors from gr...
Continue reading

How Soon After Quitting Smoking Does Bladder Cancer Risk Decrease?

One of the biggest risk factors for bladder cancer is smoking. Evidence has shown that former smokers have a reduced risk of bladder cancer compared with current smokers, but how long does it take after quitting for that risk to decrease, and how much does the risk decrease compared with that of never-smokers? According to a new study analyzing bladder cancer risk in postmenopausal women, former smokers' bladder cancer risk decreases by 25% within the first 10 years after quitting and continues ...
Continue reading

FDA Approves Erdafitinib for Metastatic Urothelial Carcinoma

Erdafitinib (Balversa™, Janssen Pharmaceutical Companies) was recently granted FDA approval for patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Erdafitinib targets genetic alterations that occur in FGFRs, which regulate important biological processes, including cell g...
Continue reading

Advanced Renal-Cell Carcinoma: Potential First-Line Treatment

​ A phase 3 clinical trial has found that in previously untreated patients with advanced renal-cell carcinoma (RCC), avelumab plus axitinib improves progression-free survival and objective response compared with sunitinib. Sunitinib is an antiangiogenic drug, meaning that it prevents tumors from growing their own blood vessels. It is considered standard of care as a first-line therapy for patients with advanced RCC. However, many patients either have inherent resistance to antiangiogenic drugs o...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.